Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP-450 Phase 2 Extension for Migraine Prevention
NCT05016661Phase 2Terminated
- Sponsor
- AEON Biopharma, Inc.
- Start
- Oct 2021
- Primary completion
- Jul 2024
- Modality
- Bacterial Toxin Conjugates
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of prabotulinumtoxinA in migraine (2 arms), sponsored by AEON Biopharma, Inc. Primary endpoints: Incidence of Treatment Emergent Adverse Events at 52 weeks and Change in Monthly Migraine Days at 52 weeks. Started Oct 2021; status: terminated.
02
Drugs
prabotulinumtoxinA
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05016661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05016661.